Defined Health rebrands as Cello Health BioConsulting

15 November 2018

18 months after joining Cello Health, US biotech consultancy Defined Health has been rebranded as Cello Health BioConsulting. The arm, which focuses on pharma and life sciences biotechnology, will operate within Cello Health’s consulting business unit – Cello Health Consulting.

London-based Cello Health offers research, communications, and advisory services to clients in the pharmaceutical, biotechnology, and health sectors. Its Cello Health Consulting division offers strategy consulting services to healthcare clients – with offerings ranging from early asset development and commercialization to competitor strategy. Cello Health Insight, meanwhile, focuses on market research, and has worked with every pharma company in the Global Fortune 500. Finally, Cello Health Communications creates compelling brand communications and engagement strategies to support clinical and commercial success.

The company has US offices in New York, Chicago, San Francisco, Philadelphia, and Yardley, PA, and UK offices in London and Farnham. Cello Health employs over 500 researchers, scientists, and strategists in Britain and the United States.Cello Health BioConsultingNow, the company has announced that it is rebranding Defined Health – a New Jersey-based consultancy focusing on early stage biotechnology – to Cello Health BioConsulting. Acquired 18 months earlier, the company name change reflects the increased alignment of strategic, scientific, and consulting resources that has taken place since Defined Health joined Cello Health in 2017.

Founded in 1983, Defined Health offers business development strategy services to life sciences firms focusing on biotech – which fights diseases and health risks through the harnessing of cellular and biomolecular processes. The team’s in-depth experience bridges clinical practice, drug development, business development, and commercial strategy, with strong expertise in oncology, rare diseases, and neuroscience, among others.

Now, operating as Cello Health BioConsulting, the former Defined Health team is enhanced by a synergistic relationship with Cello Health Consulting’s strategic marketing and commercial expertise.

"Ultimately, it is our people that our clients value, and we are not going to disrupt the client-driven approach that the Defined Health team has always delivered," said Ginger Johnson, CEO of Defined Health. "Cello Health BioConsulting will continue to be led by the same established senior leadership team operating from Florham Park, NJ.”

“As part of the Cello Health Consulting capability, our clients will now have access to over 80 consultants globally, with a unique combination of deep scientific sophistication and relevant strategic and commercial insights through senior industry and consulting expertise."

According to the company, the pharma and life sciences industry is evolving rapidly, and science-driven biotechs need to consider commercial implications early in the development cycle. "Given the trend toward compressed timelines from discovery to approval, an increasing focus on smaller patient populations, and the need for biotechs (as well as large Pharma) to navigate the fine line between scientific and commercial risk, we believe that our clients, even the most science-driven biotechs, now need to consider commercial issues early on and will benefit from the unique combination of scientific, strategic and commercial expertise we will now deliver,” said Ed Saltzman, Executive Chairman and Founder of Defined Health.


North Highland welcomes Amy Andersen as its healthcare leader

25 March 2019

Management consulting firm North Highland has hired Amy Andersen as a vice president and leader of its healthcare consulting segment. Andersen has more than 20 years of healthcare industry experience. She will be based out of the firm’s San Francisco office.

In her new role, Andersen will help clients navigate the changing healthcare landscape while developing strategies that drive value, quality, access, and efficiency.

Andersen has supported an array of healthcare and technology clients in the areas of strategy, innovation, mergers and acquisitions, and transformation. She has deep expertise in value-based care, physician engagement, provider contracting, regulatory compliance and policy, data and analytics, and quality and payment metrics.

Before joining North Highland, she founded and led Andersen Health Advisors, serving as a principal strategy advisor to Stanford University's Clinical Excellence Research Center. Before that, she spent two years as an executive partner and healthcare provider lead partner at IBM, where she created and led go-to-market strategy for the tech giant’s North American healthcare provider business.

North Highland welcomes Amy Andersen as its healthcare leader

Andersen was also a VP and partner at Philips, leading the development of a patient-centered enterprise care management redesign solution and achieving a threefold increase in the pipeline of the firm’s federal and state healthcare service line.

She additionally spent nearly two years at Booz Allen Hamilton, where she served as practice leader of the healthcare payor and provider consulting offering. In the role, she crafted the practice’s overall strategy, while working on major projects like a $30 million advisory engagement to a premier State Health Insurance Exchange under the Affordable Care Act.

"Amy is a skilled healthcare leader with experience advising high growth health and global technology companies," John Norkus, managing director of North Highland, said. "She is an industry thought leader and subject matter expert that motivates teams to build partnerships and execute strategic growth."

Related: North Highland elects CEO Dan Reardon as chairman of the board